Thomas Krams1, Adeline Ruyssen-Witrand2, Delphine Nigon3, Yannick Degboe3, Gabriel Tobon4, Bruno Fautrel5, Francis Berenbaum6, Alain Cantagrel3, Arnaud Constantin2. 1. Rheumatology, Toulouse University Hospital Purpan, place du Docteur-Joseph-Baylac, 31300 Toulouse, France. Electronic address: Thomaskrams@gmail.com. 2. Rheumatology, Toulouse University Hospital Purpan, place du Docteur-Joseph-Baylac, 31300 Toulouse, France; INSERM/UPS Toulouse III, UMR 1027, 31300 Toulouse, France. 3. Rheumatology, Toulouse University Hospital Purpan, place du Docteur-Joseph-Baylac, 31300 Toulouse, France. 4. Brittany University, Hopital Morvan, 29000 Brest, France. 5. Rheumatology, Pitié-Salpêtrière Hospital, AP-HP, 75013 Paris, France; UPMC, institut Pierre-Louis d'épidémiologie et santé publique, GRC-08, 75013 Paris, France. 6. Department of Rheumatology, University Pierre-et-Marie-Curie Paris VI, Saint-Antoine hospital, "Department Hospitalo-Universitaire Inflammation-Immunopathology-Biotherapy" (I2B), AP-HP, 75012 Paris, France; INSERM/CDR Saint-Antoine, UMRS 938, 75012 Paris, France.
Abstract
OBJECTIVES: To investigate whether age at disease onset determines clinical, radiographic or functional outcomes in a cohort of early RA. METHODS: The ESPOIR cohort is a multicenter cohort of patients with early arthritis. We selected patients fulfilling the 2010 ACR/EULAR criteria for RA during the first 3years of follow-up. Patients were pooled into 3 groups by age at RA onset: <45years (young-onset RA [YORA]), 45 to 60years (intermediate-onset RA [IORA]) and>60years (late-onset RA [LORA]). The following outcomes were compared at baseline and during the first 3years of follow-up: Simple Disease Activity Index (SDAI) remission rate, one additional erosion, Health Assessment Questionnaire Disability Index (HAQ-DI)<0.5 and first disease-modifying anti-rheumatic drug (DMARD) continuation rate. RESULTS: We included 698 patients (median [interquartile range] age 50.3 [39.8-57.2]years), 266 YORA, 314 IORA, and 118 LORA. At 1year, SDAI remission was greater for YORA than IORA and LORA (P<0.0001). Having at least one additional erosion was greater for LORA and IORA than YORA after 1year (P=0.009) and 3years (P=0.017). The proportion of patients with HAQ score<0.5 was greater for YORA than IORA and LORA at 1 (P=0.007), 2 and 3years. First DMARD continuation rate was lower for YORA than other groups during the 3years (P=0.005). CONCLUSIONS: In a cohort of early RA, young age at disease onset is associated with high rate of remission at 1year, no radiographic progression at 3years and low functional score during 3-year follow-up.
OBJECTIVES: To investigate whether age at disease onset determines clinical, radiographic or functional outcomes in a cohort of early RA. METHODS: The ESPOIR cohort is a multicenter cohort of patients with early arthritis. We selected patients fulfilling the 2010 ACR/EULAR criteria for RA during the first 3years of follow-up. Patients were pooled into 3 groups by age at RA onset: <45years (young-onset RA [YORA]), 45 to 60years (intermediate-onset RA [IORA]) and>60years (late-onset RA [LORA]). The following outcomes were compared at baseline and during the first 3years of follow-up: Simple Disease Activity Index (SDAI) remission rate, one additional erosion, Health Assessment Questionnaire Disability Index (HAQ-DI)<0.5 and first disease-modifying anti-rheumatic drug (DMARD) continuation rate. RESULTS: We included 698 patients (median [interquartile range] age 50.3 [39.8-57.2]years), 266 YORA, 314 IORA, and 118 LORA. At 1year, SDAI remission was greater for YORA than IORA and LORA (P<0.0001). Having at least one additional erosion was greater for LORA and IORA than YORA after 1year (P=0.009) and 3years (P=0.017). The proportion of patients with HAQ score<0.5 was greater for YORA than IORA and LORA at 1 (P=0.007), 2 and 3years. First DMARD continuation rate was lower for YORA than other groups during the 3years (P=0.005). CONCLUSIONS: In a cohort of early RA, young age at disease onset is associated with high rate of remission at 1year, no radiographic progression at 3years and low functional score during 3-year follow-up.
Authors: Bilal F Samhouri; Robert Vassallo; Sara J Achenbach; Vanessa L Kronzer; John M Davis; Elena Myasoedova; Cynthia S Crowson Journal: Arthritis Care Res (Hoboken) Date: 2022-01-07 Impact factor: 5.178
Authors: Katie Bechman; Anuoluwapo Oke; Mark Yates; Sam Norton; Elaine Dennison; Andrew P Cope; James B Galloway Journal: Rheumatology (Oxford) Date: 2020-09-01 Impact factor: 7.580
Authors: Debbie M Boeters; Lukas Mangnus; Sofia Ajeganova; Elisabet Lindqvist; Björn Svensson; René E M Toes; Leendert A Trouw; Tom W J Huizinga; Francis Berenbaum; Jacques Morel; Solbritt Rantapää-Dahlqvist; Annette H M van der Helm-van Mil Journal: Arthritis Res Ther Date: 2017-05-31 Impact factor: 5.156